A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers.
source https://www.sciencedaily.com/releases/2020/12/201209115232.htm
Thursday, 10 December 2020
Related Posts
As climate warms, summer monsoons to produce less streamflow
Biosensors require robust antifouling protection
Marine organisms use previously undiscovered receptors to detect, respond to light
Research finds COVID plasma donation is fuelled by kindness
Neutrons probe molecular behavior of proposed COVID-19 drug candidates
Lack of ICU beds tied to thousands of excess COVID-19 deaths, study finds
0 comments: